BackGalectin Therapeutics Overview

Galectin Therapeutics Other Current Assets

Track Galectin Therapeutics's other current assets ($1.4M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$1.39M
16.06% YoYΔ $-266000.00 vs prior year quarter

Peer average / median

Loading

Galectin Therapeutics Other Current Assets History

Loading

Galectin Therapeutics vs. peers: Other Current Assets Comparison

Loading

Galectin Therapeutics Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Galectin Therapeutics (GALT) FAQ

Galectin Therapeutics (GALT) currently reports a other current assets of $1.4M as of June 2026. That compares with $1.7M in the prior-year period — down 16.1% year over year. Use the charts on this page to explore Galectin Therapeutics's other current assets history and peer comparisons.

Galectin Therapeutics's other current assets decreased from $1.7M to $1.4M — a 16.1% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Galectin Therapeutics reported $1.4M in other current assets as of June 2026. That compares with $1.7M in the prior-year period — down 16.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current assets of $1.4M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Galectin Therapeutics, and consider following GALT for alerts when major investors trade the stock.

Galectin Therapeutics is classified in the Healthcare sector. On other current assets, it currently shows $1.4M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GALT with unrelated industries.